


## Sevasemten

Cat. No.:	HY-148799	
CAS No.:	2417395-15-2	
Molecular Formula:	C <sub>16</sub> H <sub>11</sub> F <sub>4</sub> N <sub>5</sub> O <sub>2</sub>	
Molecular Weight:	381.28	
Target:	Myosin	
Pathway:	Cytoskeleton	
Storage:	Powder	-20°C 3 years
	In solvent	-80°C 6 months
		-20°C 1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 250 mg/mL (655.69 mM; Need ultrasonic)				
	Preparing Stock Solutions	Solvent \ Mass \ Concentration	1 mg	5 mg	10 mg
		1 mM	2.6227 mL	13.1137 mL	26.2274 mL
		5 mM	0.5245 mL	2.6227 mL	5.2455 mL
	10 mM	0.2623 mL	1.3114 mL	2.6227 mL	
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (5.46 mM); Clear solution				

### BIOLOGICAL ACTIVITY

Description	Sevasemten is an allosteric inhibitor of skeletal muscle myosin. Sevasemten exhibits selectively myosin inhibition with IC <sub>50</sub> s of ≤10 μM (skeletal), >100 μM (cardiac), respectively <sup>[1][2]</sup> .
-------------	--

### REFERENCES

[1]. Russell Alan, et al. Preparation of substituted pyridazinones for use in the treatment of neuromuscular diseases: World Intellectual Property Organization, WO2021231615. 2021-11-18.

[2]. WHO Drug Information-World Health Organization (WHO).

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA